Stay up-to-date on current diabetes themes, proven therapeutic options, and knowledge resources and tools for you and your patients, and find detailed information on Novo Nordisk diabetes products.
These links take you directly to resources found on Web sites designed
specifically for healthcare professionals.
NovoPayerLink is an online portal for medical and pharmacy
directors, employers, and healthcare institutions that
provides information and tools to support diabetes
management programs. Want to learn about how diabetes
trends affect your member populations, or how your
organization can work to improve patient outcomes? Current
users can log in from here.
To become a user, contact your Novo Nordisk Account
Executive, or you can request access.
The BlueSheet asked Jeremy Shepler, director, Patient Centric Strategy & Solutions for Novo Nordisk, for his perspective on the IOM report and to discuss what being patient centric means for Novo Nordisk.
Today Novo Nordisk announced the formation of GLAM™ (Great Life After Menopause), an alliance made up of five leading women’s health advocates and a leading OB/GYN that will encourage the millions of women whose lives are disrupted by a “silent symptom” of menopause to speak up and seek help.
Novo Nordisk announced today that the U.S. Food and Drug Administration has granted 510(k) clearance for the insulin device NovoPen Echo®. This marks the first and only pen device in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection.
Charlie Kimball has become the first and only licensed driver with diabetes to win an IndyCar race. This milestone was achieved at the Honda Indy 200 at Mid-Ohio on Sunday.
Diabetes Advocacy AllianceTM works to improve the lives of people with diabetes and prediabetes. We asked Tekisha Dwan Everette, PhD, managing director of Federal Government Affairs for ADA and Martha Rinker, JD, chief Advocacy officer for AADE to share their thoughts on the work of the DAA and its priority activities.
Novo Nordisk and IZOD IndyCar Series driver Charlie Kimball today kicked off a new contest asking people to support Charlie by encouraging their friends and family to join the Race with Insulin® crew.
Chip Ganassi Racing and Novo Nordisk announced today that IZOD IndyCar Series driver Charlie Kimball’s quest to educate more people about diabetes has picked up the support of his fellow Chip Ganassi Racing Teams drivers.
Headquartered in Denmark,
Novo Nordisk is a global
healthcare company with
90 years of innovation and
leadership in diabetes care.
The company also has
leading positions within
hemophilia care, growth
hormone therapy, and